Treatment of Gestational Choriocarcinoma with WHO Modified Prognostic Score ≥ 7 (High Risk)

In gestational choriocarcinoma, the WHO modified prognostic index score for gestational trophoblastic neoplasm (GTN) determines the intensity of initial treatment. A score of 7 or higher places the patient in the high-risk category, where a specific multi-agent strategy is required from the outset.

Clinical Scenario

Patients with gestational choriocarcinoma who reach a WHO modified prognostic index score for GTN of 7 or more require multi-agent chemotherapy from the start. This threshold separates those who can be managed with single-agent treatment (score < 7) from those who need the more intensive approach defined by this protocol.

Treatment Approach

High-risk gestational choriocarcinoma warrants multi-agent chemotherapy; the EMA-CO regimen is the established first-line choice in this setting.

Complete protocol details — sequencing, management of ultra-high-risk presentations, and supportive care guidance — are available in the full regimen →

Treatment Goal

The primary endpoint is normalization of serum hCG, confirmed by normal levels measured every week for three consecutive cycles.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1136/ijgc-2023-004704

Patients with gestational choriocarcinoma who reach a WHO modified prognostic index score for GTN of 7 or higher should initially be treated with multi-agent chemotherapy.
Consider using single-agent chemotherapy in low-risk (score <7) and multi-agent chemotherapy in high risk (score of 7 or more).
The most used multi-agent regimen is EMA-CO (etoposide, methotrexate, and dactinomycin alternating with cyclophosphamide and vincristine) because of low toxicity, high complete response rates, and overall high resultant survival.
For assessing initial response to treatment, normal serum hCG levels every week for three consecutive cycles are necessary.

View source ↗